Given the fact that clinical classification standards, such as T stage, M stage, and tumor status, are vital parameters for patient outcome prediction, we continued the clinical relevance analysis by determining whether RPL32 expression could serve as an independent factor for predicting patient malignancy. The gene discussed is RPL32; the disease is neoplasm.